ImmunID

The leading specialist in Combinatorial Repertoire analysis of the immune system

Thanks to its original concept of "Immune Weather Forecast" ImmunID offers innovative immunomonitoring & diagnostic solutions to characterize immune dysfunction and analyse the impact of immunotherapy on Immune Repertoire.

Biotech & pharma segment : ImmunID solutions are used from research to clinical validation to measure efficacy and toxicity risk of molecules such as Monoclonal antibodies (anti-CD20...), Interleukins (IL2, IL7...), or vaccines (prophylactic or therapeutic).

Medical segment : ImmunID solutions are used to diagnose certain pathologies such as Lymphoma and Leukemia, and to monitor immunodeficiency and follow up disease progression and immunomodulators efficacy. Pathologies mainly concerned are blood cancers, infectious diseases, cancers, autoimmune diseases.

ImmunID  : first biotech to benefit from the pre-funding of subsidies

As part of the funding of its R&D projects, ImmunID has just benefited from the latest funding innovation program set up jointly by OSEO, Place Financière de Lyon, and BNP-Paribas. This advance loan on subsidies is a guarantee by OSEO that helps to speed up the launch of R&D programs accredited by Competitiveness Clusters, including Lyonbiopôle.

Complete press release